- Home
- » Tags
- » Gilteritinib
Top View
- FLT3 Mutated Acute Myeloid Leukemia: 2021 Treatment Algorithm Naval Daver 1, Sangeetha Venugopal1 and Farhad Ravandi1
- Therapeutic Vulnerabilities in FLT3-Mutant AML Unmasked by Palbociclib
- Acute Myeloid Leukemia (AML)
- Cutting Edge Molecular Therapy for Acute Myeloid Leukemia
- A Method for Overcoming Plasma Protein Inhibition of Tyrosine Kinase Inhibitors
- Outpatient Cancer Drug Benefit Program List
- Therapeutic Advances in Oncology
- 211349Orig1s000
- Triplet Therapy with Venetoclax, FLT3 Inhibitor and Decitabine for FLT3-Mutated Acute Myeloid Leukemia Abhishek Maiti1, Courtney D
- Adult Antiemetic Management of Chemotherapy-Induced Nausea
- Supplementary Table 1. Summary of FDA-Approved Anticancer Cytotoxic Drugs at May 2019
- Leukemia Insights Newsletter March 2021
- Emetogenic Potential of Antineoplastic Agents
- Xospata® (Gilteritinib) (Oral) Document Number: IC-0418 Last Review Date: 01/03/2019 Date of Origin: 01/03/2019 Dates Reviewed: 01/2019
- Mapping the SARS-Cov-2–Host Protein–Protein Interactome
- Optimizing the Management of Acute Myeloid Leukemia: Individualized Therapy
- Oncology Agents Policy #: Rx.01.67
- American Journal Hematology/ Oncology®
- Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?
- FLT3 Tyrosine Kinase Inhibitors for the Treatment of Fit and Unfit Patients
- October 2017 a View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS
- Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments
- Vol. 85 Thursday, No. 108 June 4, 2020 Pages 34353–34492
- Tyrosine Kinase Inhibitors - Oral
- Gilteritinib) Tablets, for Oral Use Initial U.S
- Targeting AML-Associated FLT3 Mutations with a Type I Kinase Inhibitor
- Clinical Considerations for the Use of FLT3 Inhibitors in Acute Myeloid Leukemia T ⁎ Taylor M
- Emetic Risk of Single Intravenous Antineoplastic Agents in Adults
- AXL Receptor Tyrosine Kinase As a Promising Anti-Cancer Approach: Functions, Molecular Mechanisms and Clinical Applications
- An Open Access Database of Licensed Cancer Drugs Pan Pantziarka 1,2, §, Rica Capistrano 1, Arno De Potter 3, Liese Vandeborne 1, Gauthier Bouche 1
- A Profile of the Progress with Targeted Therapy in AML
- Xospata (Gilteritinib) Effective 01/01/2021 Plan Masshealth
- 16722836) Imatinib (Pubmed CID: 123596) in the Treatment of Urothelial Bladder Cancers
- Chemo Agents for Specific Cancers
- Venetoclax Combines Synergistically with FLT3 Inhibition to Effectively
- Heat Shock Protein 90 Inhibitors Overcome the Resistance to Fms-Like Tyrosine Kinase 3 Inhibitors in Acute Myeloid Leukemia
- 409 Oncology Drugs
- Role of OATP1B1 and OATP1B3 in Drug-Drug Interactions Mediated by Tyrosine Kinase Inhibitors
- Will New Agents Impact Survival in AML? T ∗ Jacob M
- FDA Approves Gilteritinib for Relapsed Or Refractory Acute Myeloid Leukemia
- Venetoclax-Based Regimens for Relapsed/Refractory Acute Myeloid Leukemia in a Real-Life Setting: a Retrospective Single-Center Experience
- Leukemia Insights Newsletter April 2020 AML
- 2020 Annual Report
- United States Securities and Exchange Commission
- Pharmacokinetic Profile of Gilteritinib: a Novel FLT-3 Tyrosine Kinase Inhibitor
- Gilteritinib: a Novel FLT3 Inhibitor for Acute Myeloid Leukemia Juanjuan Zhao1, Yongping Song1* and Delong Liu1,2*
- Emerging Immunotherapy for Acute Myeloid Leukemia
- New Therapeutic Approaches for Acute Myeloid Leukaemia